本帖最后由 老马 于 2012-1-13 21:20 编辑
% w8 D$ Y. B& T! n: s& M! G( z @
爱必妥和阿瓦斯丁的比较% ?- }( e) b5 o- N
* g( I& c G- m- Z8 Ehttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/. G4 A b) U$ ^7 q6 G. T
- P5 S) V( Y" U# ^
4 A" {1 D# z3 f6 x2 N
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 i) R* I$ B5 v6 r
==================================================, E- S7 j( Y0 v# L8 A6 p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 l1 U& c8 F9 N7 ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& j& [ B4 z! mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ p" \! E9 i# ~ {
|